BRAF mutation testing for the choice of melanoma treatment

Close metadata

Recommended articles:

Human diseases treatment via enema fecal microbiota transplantation. Methodological recommendations. Russian Journal of Preventive Medicine. 2024;(6):79-87

Artificial intelligence in dermatology: opportunities and prospects. Russian Journal of Clinical Dermatology and Venereology. 2024;(3):246-252

Cognitive behavioral therapy in the treatment of patients with chronic migraine and concomitant chronic insomnia: a prospective, randomized trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):110-117

Late-onset schizophrenia and schizophrenia-like psychosis with very late onset. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):32-40

Melanoma metastasis to the brachial plexus and median nerve. A rare clinical case. Burdenko's Journal of Neurosurgery. 2024;(5):93-101

Unresolved problem: Chemotherapy-Induced Peripheral Neuropathy. P.A. Herzen Journal of Oncology. 2024;(5):76-81

Simultaneous closure of plantar extensive soft tissue defect using skin graft and lipofilling after resection of melanoma. Plastic Surgery and Aesthetic Medicine. 2024;(4-2):86-90

Non-invasive automated methods for the diagnosis of periorbital skin tumors. Russian Annals of Ophthalmology. 2024;(5):137-145

Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90

Clinical Case of Tattoo Pigment Detection in Sentinel Lymph Nodes Against the Background of Melanoma. Russian Journal of Clinical Dermatology and Venereology. 2024;(6):679-683

Individual life-time risk of melanoma in white residents of highly developed countries may be as high as 2%. Continuing rise of melanoma incidence is directly related to the improving life standards, especially to growing opportunities of attending sea resorts and getting tanned. Melanoma is usually highly aggressive and resistant to standard cytotoxic therapy, therefore 5-years survival of patients with the metastatic disease does not exceed 10-15%. Approximately 50% of melanomas contain point mutation in codon 600 of the BRAF kinase. Specific inhibitors of activated BRAF have demonstrated unprecedented therapeutic efficacy, thus BRAF testing has become a mandatory component of treatment planning for inoperable melanoma. This review discusses key issues, which are related to various clinical, morphological, and molecular genetic aspects of determination of BRAF status in metastatic melanoma.

Keywords:

melanoma

therapy

BRAF gene mutations

Authors:

Imianitov E.N.

NII onkologii im. N.N. Petrova, Sankt-Peterburg

List of references:

Amanuel B., Grieu F., Kular J., Millward M., Iacopetta B. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology 2012; 44: 357-359.
Anderson S., Bloom K.J., Vallera D.U., Rueschoff J., Meldrum C., Schilling R., Kovach B., Lee J.R., Ochoa P., Langland R., Halait H., Lawrence H.J., Dugan M.C. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012 (in press).
Arkenau H.T., Kefford R., Long G.V. Targeting BRAF for patients with melanoma. Br J Cancer 2011; 104: 392-398.
Bauer J., Büttner P., Murali R., Okamoto I., Kolaitis N.A., Landi M.T., Scolyer R.A., Bastian B.C. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24: 345-351.
Berwick M., Erdei E., Hay J. Melanoma epidemiology and public health. Dermatol Clin 2009; 27: 205-214, viii.
Broekaert S.M., Roy R., Okamoto I., van den Oord J., Bauer J., Garbe C., Barnhill R.L., Busam K.J., Cochran A.J., Cook M.G., Elder D.E., McCarthy S.W., Mihm M.C., Schadendorf D., Scolyer R.A., Spatz A., Bastian B.C. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 2010; 23: 763-770.
Capper D., Berghoff A.S., Magerle M., Ilhan A., Wöhrer A., Hackl M., Pichler J., Pusch S., Meyer J., Habel A., Petzelbauer P., Birner P., von Deimling A., Preusser M. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012; 123: 223-233.
Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R.J., Flaherty K.T., McArthur G.A. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364, 2507-2516.
Colombino M., Capone M., Lissia A., Cossu A., Rubino C., De Giorgi V., Massi D., Fonsatti E., Staibano S., Nappi O., Pagani E., Casula M., Manca A., Sini M., Franco R., Botti G., Caracò C., Mozzillo N., Ascierto P.A., Palmieri G. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012 (in press).
Curtin J.A., Fridlyand J., Kageshita T., Patel H.N., Busam K.J., Kutzner H., Cho K.H., Aiba S., Bröcker E.B., LeBoit P.E., Pinkel D., Bastian B.C. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
Davies M.A., Gershenwald J.E. Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am 2011; 20: 165-80.
Doré J.F., Chignol M.C. Tanning salons and skin cancer. Photochem Photobiol Sci 2012; 11: 30-37.
Eckhart L., Bach J., Ban J., Tschachler E. Melanin binds reversibly to thermostable DNA polymerase and inhibits its activity. Biochem Biophys Res Commun 2000; 271: 726-730.
Edwards R.H., Ward M.R., Wu H., Medina C.A., Brose M.S., Volpe P., Nussen-Lee S., Haupt H.M., Martin A.M., Herlyn M., Lessin S.R., Weber B.L. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 2004; 41: 270-272.
Ellison G., Donald E., McWalter G., Knight L., Fletcher L., Sherwood J., Cantarini M., Orr M., Speake G. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010; 29:132.
Erdei E., Torres S.M. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther 2010; 10, 1811-1823.
Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
Greaves M. Cancer causation: the Darwinian downside of past success? Lancet Oncol 2002; 3: 244-251.
Halait H., Demartin K., Shah S., Soviero S., Langland R., Cheng S., Hillman G., Wu L., Lawrence H.J. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol 2012; 21: 1-8.
Hall-Jackson C.A., Eyers P.A., Cohen P., Goedert M., Boyle F.T., Hewitt N., Plant H., Hedge P. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 1999; 6: 559-568.
Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-21.
Kanavy H.E., Gerstenblith M.R. Ultraviolet radiation and melanoma. Semin Cutan Med Surg 2011; 30, 222-228.
Kimple A.J., Bosch D.E., Giguère P.M., Siderovski D.P. Regulators of G-protein signaling and their G α substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev 2011; 63: 728-749.
Lee J.H., Choi J.W., Kim Y.S. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011; 164: 776-784.
Lin J., Goto Y., Murata H., Sakaizawa K., Uchiyama A., Saida T., Takata M. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer 2011; 104: 464-468.
Long G.V., Menzies A.M., Nagrial A.M., Haydu L.E., Hamilton A.L., Mann G.J., Hughes T.M., Thompson J.F., Scolyer R.A., Kefford R.F. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-1246.
Lovly C.M., Dahlman K.B., Fohn L.E., Su Z., Dias-Santagata D., Hicks D.J., Hucks D., Berry E., Terry C., Duke M., Su Y., Sobolik-Delmaire T., Richmond A., Kelley M.C., Vnencak-Jones C.L., Iafrate AJ., Sosman J., Pao W. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012; 7: e35309.
MacKie R.M., Hauschild A., Eggermont A.M. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009; 20 (suppl 6): vi1-7.
Menzies A.M., Haydu L.E., Visintin L., Carlino M.S., Howle J.R., Thompson J.F., Kefford R.F., Scolyer R.A., Long G.V. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18: 3242-3249.
Miller A.J., Mihm M.C. Jr. Melanoma. N Engl J Med. 2006; 355: 51-65.
Nikiforov Y.E., Nikiforova M.N. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011; 7: 569-580.
Patrick R.J., Fenske N.A., Messina J.L. Primary mucosal melanoma. J Am Acad Dermatol 2007; 56: 828-834.
Pinzani P., Santucci C., Mancini I., Simi L., Salvianti F., Pratesi N., Massi D., De Giorgi V., Pazzagli M., Orlando C. BRAFV600E detection in melanoma is highly improved by COLD-PCR. Clin Chim Acta 2011; 412: 901-905.
Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464: 427-430.
Qi R.Q., He L., Zheng S., Hong Y., Ma L., Zhang S., Zhao L., Guo X., Wang Y., Yu J.Y., Fu L., Zhang W., Long T., Zhang C., Chen G., Lin J., Wang C., Zhou L., Mi Q., Weiland M., Chen J.Z., McHenga S.S., Wang Y.K., McHepange U., Wang Z., Chen H.D., Gao X.H. BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han. J Invest Dermatol 2011; 131: 1129-1138.
Rubinstein J.C., Sznol M., Pavlick A.C., Ariyan S., Cheng E., Bacchiocchi A., Kluger H.M., Narayan D., Halaban R. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010; 8: 67.
Si L., Kong Y., Xu X., Flaherty K.T., Sheng X., Cui C., Chi Z., Li S., Mao L., Guo J. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 2012; 48: 94-100.
Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., Hersey P., Kefford R., Lawrence D., Puzanov I., Lewis K.D., Amaravadi R.K., Chmielowski B., Lawrence H.J., Shyr Y., Ye F., Li J., Nolop K.B., Lee R.J., Joe A.K., Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-714.
Weber A., Hengge U.R., Urbanik D., Markwart A., Mirmohammadsaegh A., Reichel M.B., Wittekind C., Wiedemann P., Tannapfel A. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest 2003; 83: 1771-1776.
Yancovitz M., Litterman A., Yoon J., Ng E., Shapiro R.L., Berman R.S., Pavlick A.C., Darvishian F., Christos P., Mazumdar M., Osman I., Polsky D. Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS One 2012; 7: e29336.
Zimmer L., Hillen U., Livingstone E., Lacouture M.E., Busam K., Carvajal R.D., Egberts F., Hauschild A., Kashani-Sabet M., Goldinger S.M., Dummer R., Long G.V., McArthur G., Scherag A., Sucker A., Schadendorf D. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; 30: 2375-2383.

Close metadata